ArticleCellular oncology (Dordrecht, Netherlands)2026
A novel molecular classifier enabling identification and prediction on immunotherapeutic response for MYCN-low pediatric neuroblastoma.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeNeuroblastoma (NB) is a pediatric malignant solid tumor arising from peripheral neural crest cells, characterized by significant heterogeneity. Previous studies have stratified NB patients into risk groups based on pivotal genetic changes, but the suboptimal clinical outcomes of NB underscore the need for a more precise individualized grading system to guide the selection of novel therapeutic strategies.
methodsIn this study, we developed a dense neural network molecular classifier utilizing bulk transcriptomics data from the UCSC Treehouse database and applied it to a single-center cohort.
resultsThe neural network molecular classifier on bulk transcriptomics refined the classification in both high-risk and low-risk groups by the traditional classification method. The classifier identified four molecular subtypes: High-risk MYCN-high NB (HR1), High-risk MYCN-low NB (HR2), Low/Intermediate-risk NB (LR1), and Low/Intermediate-risk GNB (LR2). By applying the new classifier, we identified factors such as PIK3R1, GATA2, and EYA1 that may be associated with a low-risk, differentiated ADRN-subtype NB, in addition to the classical adrenergic fate-determining factors PHOX2B, ASCL1, ALK, and GATA3. Additionally, we observed elevated GD2 and CTLA-4 expression in the High-risk MYCN-low NB group, which may serve as a potential clue for the development of personalized immunotherapeutic strategies.
conclusionOur model details the current NB risk stratification at the transcriptomic level with a molecular classifier and offers potentially more personalized immunotherapeutic strategies for High-risk MYCN-low NBs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.